{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

7_Direct to consumer advertising in oncology - Abel et al.

7_Direct to consumer advertising in oncology - Abel et al....

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
Abel, Penson, Joffe et al. 223 www.TheOncologist.com largest part of newspaper revenues. Cures for ailments from dandruff to rheumatism were peddled, but claims were not regulated [1]. The next important year with respect to regulation of direct-to-consumer advertising was 1938, when the Food, Drug, and Cosmetic Act was passed. The newly-created FDA was given authority over the labeling of drugs, but the Federal Trade Commission was charged to “regulate” drug promotion and advertising [9]. In 1962, The Kefauver-Harris Act was passed, requiring that all drugs be proven to be both safe and effective. This act also transferred the authority for oversight of prescription drug promotional material to the FDA. This era saw the birth of the concept of “fair balance,” the idea that an advertisement for a medication should include both a discussion of ben- efits as well as risks and side effects. Most advertisements were still directed solely at providers [1, 9]. In 1981, the first modern direct-to-consumer adver- tisement appeared in Reader’s Digest for the pneumonia vaccine Pneumovax ® (Merck & Co., Inc.) [9]. That same year, the pharmaceutical lobbyists proposed that consum- ers should be allowed to reap what they saw as the educa- tional benefits of direct-to-consumer advertising. Attitudes toward the physician–patient partnership were also chang- ing, and the political climate became more favorable to the pharmaceutical industry. In 1985, after a brief moratorium
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

Ask a homework question - tutors are online